TY  - JOUR
T1  - Inequities in Antiviral Therapy for Diabetic Individuals Affected by COVID-19
A1  - Andreea Fitero
A1  - Nicoleta Negruț
A1  - Delia Carmen Nistor Cseppento
A1  - Delia MirelaTit
A1  - Paul Andrei Negru
A1  - Cristian Bustea
A1  - Andrei Flavius Radu
A1  - Simona Gabriela Bungau
JF  - Annals of Pharmacy Practice and Pharmacotherapy
JO  - Ann Pharm Pract Pharmacother
SN  - 3062-4436
Y1  - 2023
VL  - 3
IS  - 1
DO  - 10.51847/BAIbQWifek
SP  - 9
EP  - 20
N2  - Diabetes patients are more vulnerable to COVID-19 infections, which can cause serious respiratory conditions. In this study, the effect of the antiviral medication with molnupiravir and favipiravir was compared in COVID-19 patients with underlying diabetes. The current investigation included a cohort of 100 people who had been diagnosed with diabetes, had a SARS-CoV-2 infection, and had been admitted sequentially. The antiviral drugs were administered to these patients according to regional recommendations:  favipiravir was administered for 10 days for group F (51 instances), while molnupiravir was administered for 5 days to group M (49 cases). Compared to group M, group F showed a higher mean hospitalisation rate (11.29 ± 2.27 vs. 7.14 ± 3.16, P < 0.001). At the end of treatment, group M’s risk score for severe evolution was less statistically significant (156.29 ± 61.32; 160.59 ± 59.41, P < 0.001). When molnupiravir was administered instead of favipiravir, the number of deaths among COVID-19 patients was reduced [2 (4.08%) vs. 9 (17.65%), P = 0.034]. Molnupiravir outperformed favipiravir when it came to treating SARS-CoV-2 infections in diabetic patients. Diagnosing or treating diabetes is essential to halting the critical course of COVID-19 in individuals. Its promise in the treatment of SARS-CoV-2-infected individuals requires more investigation.
UR  - https://galaxypub.co/article/inequities-in-antiviral-therapy-for-diabetic-individuals-affected-by-covid-19-dcvzvwqfjxh7pmo
ER  -